NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Atezolizumab
Related studies linked through entity extraction aliases.
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
- Status
- TERMINATED
- Phase
- PHASE2
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
- Status
- TERMINATED
- Phase
- PHASE2
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Status
- RECRUITING
- Phase
- PHASE2
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
- Status
- TERMINATED
- Phase
- PHASE4
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1